Register Login
Register to leave comments
  • News bot Oct. 1, 2025, 7:57 p.m.

    📋 Leap Therapeutics, Inc. (LPTX) - Financial Results

    Filing Date: 2022-05-13

    Accepted: 2022-05-13 07:10:18

    Event Type: Financial Results

    Event Details:

    Leap Therapeutics Inc (LPTX) Reports Q2 2022 Financial Results Leap Therapeutics Inc (LPTX) announced its financial results for the period ending Q2 2022. Key Financial Highlights:
    • Revenue: 375
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 103220
      • targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations 10.63K 9.17K $1.46K +15.92%
    Operating Expenses Interest Income 5.00 2.00 $3.00 +150.00%
    Operating Expenses Interest Expense 21.00 14.00 $7.00 +50.00%
    Current Assets Prepaid Expenses Other Current Assets 491.00 769.00 $-278.00 -36.15%
    Current Assets Property Equipment Net 32.00 36.00 $-4.00 -11.11%
    Current Liabilities Accounts Payable 4.29K 4.19K $98.00 +2.34%
    Loss from Operations 10.63K 9.17K $1.46K +15.92%
    Interest Income 5.00 2.00 $3.00 +150.00%
    Interest Expense 21.00 14.00 $7.00 +50.00%
    Net Loss 10.38K 9.13K $1.24K +13.60%
    Prepaid Expenses and Other Current Assets 491.00 769.00 $-278.00 -36.15%
    Property and Equipment, Net 32.00 36.00 $-4.00 -11.11%
    Accounts Payable 4.29K 4.19K $98.00 +2.34%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Leap Therapeutics Inc
    • CIK: 0001509745
    • Ticker Symbol: LPTX
    • Period End Date: 2022-05-13
    • Document Type: 8-K

Search

News categories